Adelaide Research & Scholarship
Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/94690
| Citations | ||
| Scopus | Web of Science® | Altmetric |
|---|---|---|
|
?
|
?
|
|
| Type: | Journal article |
| Title: | Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436) |
| Author: | Falchook, G. Long, G. Kurzrock, R. Kim, K. Arkenau, H. Brown, M. Hamid, O. Infante, J. Millward, M. Pavlick, A. Chin, M. O'Day, S. Blackman, S. Curtis, C. Lebowitz, P. Ma, B. Ouellet, D. Kefford, R. |
| Citation: | Clinical Cancer Research, 2014; 20(17):4449-4458 |
| Publisher: | American Association for Cancer Research |
| Issue Date: | 2014 |
| ISSN: | 1557-3265 1557-3265 |
| Statement of Responsibility: | Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O'Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, and Richard F. Kefford |
| Abstract: | Abstract not available |
| Keywords: | Humans Melanoma Oximes Imidazoles Proto-Oncogene Proteins B-raf Protein Kinase Inhibitors Positron-Emission Tomography Treatment Outcome Drug Administration Schedule Dose-Response Relationship, Drug Mutation Adult Aged Aged, 80 and over Middle Aged Female Male |
| Rights: | © 2014 American Association for Cancer Research. |
| DOI: | 10.1158/1078-0432.CCR-14-0887 |
| Published version: | http://dx.doi.org/10.1158/1078-0432.ccr-14-0887 |
| Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.